The short version of GLP-1 analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
=== Traditional === Rotheca myricoides is used in traditional medicine to manage diabetes in the lower eastern part of Kenya. This area is populated mostly by the Kamba community. They take this medicine daily by boiling and consuming the leaves. This species is also used to treat epilepsy, arthritis, typhoid, cough, eye problems, tonsillitis, rheumatism, gonorrhoea, cancer, malaria, dysmenorrhea, sterility, and impotence. In traditional medicine, European and African cultures used the bark of the species in its powdered form, and a teaspoon is used to treat snakebites. The Masai used the root bark for East Coast fever in cattle and diarrhea in their calves. The Haya and Shambala used Rotheca myricoides for dysmenorrhoea and cough, furunculosis and swellings that are associated with debility. In various African communities, the root of the plant is also used for chest pain, colds, gum bleeding indigestion, headaches, and bathing people with convulsions. In West Africa, the plant is used for analgesic and antipyretic purposes. In Asian countries, this species has been brewed as a tea to relieve swelling and pain.
The Moloney electrode, developed in 1921, is "designed to more accurately and rapidly determine the acidity of bacterial culture broths used in antitoxin and vaccine production." Hermann F. Schott (1904–1986) in his 1933 Ph.D. thesis gave a brief description of the Moloney electrode and its use. At Connaught Laboratories during the 1920s, Moloney dealt with the diphtheria toxin, whose preparation he directed from 1924. With Charles Beecher Weld (1899–1991), he developed the first diphtheria toxoid in North America. Moloney helped to develop a detection test for diphtheria toxin (the "Moloney test") and established methods for the detection and purification of tetanus toxin and contributed to the elucidation of its antigen structure. From 1931 he headed the "Chemistry in Relation to Hygiene" department of the School of Hygiene (dealing with microbiology) of the University of Toronto. He was part of the group that successfully developed methods for producing penicillin on a large scale during WW II. Moloney and co-workers were also able to prepare a polyvalent immune serum against gas gangrene. With Anthony L. Tosoni, he provided the basis for a new method for the production of penicillin in large quantities. Moloney was deputy director of Connaught Laboratories from 1925 until his retirement in 1961, but continued to work for the company as a researcher and consultant into his ninth decade. His last publications in the early 1970s dealt with insulin resistance and insulin as antigen. Moloney held 7 U.S.
== Early life == Rose West was born Rosemary Pauline Letts, on 29 November 1953, in Northam, Devon, to William Andrew "Bill" Letts and Daisy Gwendoline Fuller after a difficult pregnancy. She was the fifth of seven children born into a poor family. Rose's mother suffered from clinical depression and was given electroconvulsive therapy both during and immediately after her pregnancy; some have argued that this treatment may have caused prenatal developmental injuries to her daughter. Rose grew up into a moody teenager, prone to daydreaming and performing poorly at school. After her parents separated she initially lived with her mother and attended Cleeve School for six months, then moved in with her father in Bishop's Cleeve, near Cheltenham, Gloucestershire. Rose's father, who suffered from schizophrenia, was prone to extreme violence and sexually abused Rose and her oldest sister, Patricia. At the onset of puberty, Rose, reportedly fascinated by her developing body, would deliberately parade naked or semi-naked around the house in the presence of her younger brother, Graham (born 1957). On numerous occasions, at the age of 13, she would creep into nine-year-old Graham's bed at nightfall and molest him and her youngest brother, Gordon.
Sources: en.wikipedia.org
Although the mechanism by which Hmd acts is unknown, the iron-containing cofactor is in part responsible for the catalytic activity. High concentrations of CO inhibit the enzyme as well, implicating iron as the center of catalysis. It has been proposed that the iron functions to bind H2 and the substrate methenyltetrahydromethanopterin, organizing these two reactants in close proximity.
The NK-92 cell line is an immortalised cell line that has the characteristics of a type of immune cell found in human blood called 'natural killer' (NK) cells. Blood NK cells and NK-92 cells recognize and attack cancer cells as well as cells that have been infected with a virus, bacteria, or fungus. NK-92 cells were first isolated in 1992 in the laboratory of Hans Klingemann at the British Columbia Cancer Agency in Vancouver, Canada, from a patient who had a rare NK cell non-Hodgkin-lymphoma. These cells were subsequently developed into a continuously growing cell line. NK-92 cells are distinguished by their suitability for expansion to large numbers, ability to consistently kill cancer cells and testing in clinical trials. When NK-92 cells recognize a cancerous or infected cell, they secrete perforin that opens holes into the diseased cells and releases granzymes that kill the target cells. NK-92 cells are also capable of producing cytokines such as tumor necrosis factor alpha (TNF-a) and interferon gamma (IFN-y), which stimulates proliferation and activation of other immune cells.
The Prausnitz–Küstner test (PK test, Prausnitz-Küstner reaction) is an immunologic test formerly used by physicians to determine if a patient has an allergic reaction to a specific antigen. The test has been replaced by the safer skin prick test. The PK test involves transferring serum from the test subject to another healthy person, essentially using the second person as a mixing vessel for antibodies and antigen. This is a pathway for transmission of blood-borne ailments like variant Creutzfeldt–Jakob disease, AIDS, and others, which is why the test is no longer recommended. Or in simple words, a test for the presence of immediate hypersensitivity in humans; test serum from an atopic individual is injected intradermally into a normal subject; the normal subject is challenged 24–48 hours later with the antigen suspected of causing the immediate hypersensitivity reaction in the atopic individual.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.